


**Cell Reports, Volume 42**

**Supplemental information**

**A structural blueprint for interleukin-21**


**signal modulation**

**Gita C. Abhiraman, Theodora U.J. Bruun, Nathanael A. Caveney, Leon L. Su, Robert A. Saxton, Qian Yin, Shaogeng Tang, Mark M. Davis, Kevin M. Jude, and K. Christopher Garcia**



**Figure S1. Structure of the IL-21 receptor complex, related to Figure 1**

**(A–B)** Size exclusion chromatography UV traces for purified IL-21R and IL-21 (A) complex and  $\gamma_C$  (B) and accompanying Coomassie-stained SDS-PAGE gel. Fractions collected for crystallization trials are indicated in red. **(C)** Wall-eyed stereo view of site IIa interface. The final 2mFo-DFc map (shown in gray) is contoured at 1.0  $\sigma$ . IL-21 shown in green,  $\gamma_C$  in pink.



**Figure S2. Cryo-electron microscopy of the IL-21 complex, related to Figure 1**


**(A)** Final model of 2:2:2 IL-21:IL-21R:γ<sub>C</sub> complex determined by cryoEM (shown in transparency, EMD ID: EMD-28278) with crystallography model docked (shown as ribbon, PDB ID: 8ENT).

**(B–C)** Size exclusion chromatography UV trace for IL-21–IL-21R–γ<sub>C</sub> complex after BS<sup>3</sup> cross-linking and accompanying Coomassie-stained SDS-PAGE gel. Fractions collected for cryo-EM studies are outlined in red.

**(D)** Cryo-EM data processing of the IL-21 complex, including representative micrograph from data acquisition. 2D class averages for hexamer, tetramer, and trimer classes and *ab initio* models generated for each class, followed by refinement scheme for the hexameric model.

**(E)** Fourier shell correlation (FSC) curve of final model.

**(F)** Orientational distribution of the complex reconstruction.



**Figure S3. Design of human IL-21 partial agonists, related to Figure 3**

(A) Coomassie-stained SDS-PAGE gel of His-tagged IL-21 variants purified by Ni-NTA.

(B) Representative gating on single Y116 cells.


(C–D) Representative histograms of pSTAT3 (C) or pSTAT1 (D) intensity in Y116 cell stimulated with wild-type IL-21 or variant.

(E) Representative histograms of pS6 intensity in Y116 cells stimulated with wild-type IL-21 or variant.

(F) Dose-response curves for phospho-STAT3 in Y116 cells stimulated with wild-type IL-21 or the indicated variants for 20 minutes and analyzed by flow cytometry. Data are mean  $\pm$  SD for two replicates, shown as percent of maximal wild-type IL-21 MFI.

(G) Time-course signaling assays for intracellular phospho-STAT3 and phospho-STAT1 in Y116 cells stimulated with 200nM IL-21 or variant for up to one hour. Data are mean  $\pm$  SD for two replicates.

(H) Dose-response curves for phospho-STAT3 in Y116 cells stimulated with wild-type IL-21 or the indicated variants for 20 minutes and analyzed by flow cytometry. Data are mean  $\pm$  SD for two replicates, shown as percent of maximal wild-type IL-21 MFI.



## Figure S4. IL-21 signaling in primary human cells


(A–B) Representative gating of primary CD4<sup>+</sup> and CD8<sup>+</sup> T cells (A) or CD19<sup>+</sup> and CD56<sup>+</sup> cells from bulk human peripheral mononuclear cells (B).

(C–F) Representative histograms of pSTAT3 intensity in CD4<sup>+</sup> (C), CD8<sup>+</sup> (D), CD19<sup>+</sup> (E) or CD56<sup>+</sup> (F) cells stimulated with wild-type IL-21, Q116T, Q116I, or no cytokine.

(G) Representative histograms of pERK intensity of MACS isolated CD19<sup>+</sup> cells stimulated with wild-type IL-21, BCR stimulation, or CD40 stimulation, corresponding to Figure 4B.

(H–I) Representative histograms of pS6 intensity of CD19<sup>+</sup> cells stimulated with wild-type IL-21, Q116T, Q116I, or no cytokine with (H) or without (I) BCR stimulation, corresponding to Figure 4C.

(J) Bar graphs quantifying mean intensity of pS6 and pERK in B cells detected by flow cytometry, corresponding to heat maps in Figure 4B–C (N=2 biological replicates, \* indicates  $P \leq 0.05$ , \*\* indicates  $P \leq 0.01$ , \*\*\* indicates  $P \leq 0.001$ , \*\*\*\* indicates  $P \leq 0.0001$  by two-way ANOVA).



**Figure S5. Characterization of IL-21 response in human tonsil organoids, related to Figure 4**

**(A)** Representative gating of naïve B cells, memory B cells, germinal center B cells (GC), pre-germinal center B cells (pre-GC), plasmablasts, and T follicular helper (Tfh) cells in human tonsil organoids.


**(B)** Plasmablast frequency (% of total B cells) and flu-specific IgG detected by ELISA from tonsil organoids cultured for 7 days with or without live attenuated influenza virus (LAIV) and 50ng/ml (high dose) or 10ng/mL (low dose) IL-21 (N=3 human donors).

**(C)** Representative titrations of flu-specific IgG detected by ELISA in human tonsil organoids from an adult and pediatric donor.

**(D)** Representative standard curves derived from broadly neutralizing antibody MEDI8852 binding to whole flu used for quantification of flu-specific antibodies in human tonsil experiments.

**(E–F)** Flu-specific IgG quantified by ELISA from tonsil organoids vaccinated with LAIV and indicated IL-21 variant on day 4 (F) and day 7 (G). IgG was quantified using broadly neutralizing flu antibody. Raw IgG values plotted as ng/mL. \* indicates  $P \leq 0.05$ , \*\* indicates  $P \leq 0.01$  by ANOVA. (N=5 human donors.)

**(G)** Titrations of flu-specific IgG detected by ELISA in human tonsil organoids derived from 5 donors, stimulated with LAIV, wild-type IL-21, Q116T, or Q116I.



**Figure S6. Autoantibody production is modulated by IL-21 variants**

**(A–B)** IgM (A) and IgG (B) against self-antigens dsDNA, Ku and La, quantified by ELISA on day 7 in tonsils cultured with 100nM IL-21 or variant. Data are mean +/- SD for five human donors.

\* indicates  $P \leq 0.05$ , \*\* indicates  $P \leq 0.01$  by one-way ANOVA.

**Table S1. Data collection and refinement statistics, related to Figure 1**

<b>Protein</b>	<b>IL-21-IL-21R-yc complex</b>
<b>PDB ID</b>	8ENT
<b>Data collection</b>	
<b>Wavelength</b>	0.9795
<b>Resolution range (Å)</b>	48.17 - 2.831 (2.932 - 2.831)
<b>Space group</b>	P1
<b>a, b, c (Å)</b>	66.167 66.464 162.684
<b><math>\alpha</math>, <math>\beta</math>, <math>\gamma</math></b>	83.338 83.708 73.098
<b>Total reflections</b>	211574 (20618)
<b>Unique reflections</b>	57754 (5757)
<b>Multiplicity</b>	3.7 (3.6)
<b>Completeness (%)</b>	91.66 (88.39)
<b>Mean I/sigma</b>	4.22 (0.66)
<b>R<sub>sym</sub></b>	0.2143 (1.636)
<b>R<sub>meas</sub></b>	0.2506 (1.914)
<b>R<sub>pim</sub></b>	0.1292 (0.9883)
<b>CC<sub>1/2</sub></b>	0.985 (0.401)
<b>CC*</b>	0.996 (0.757)
<b>Refinement</b>	
<b>Reflections used in refinement</b>	57397 (5529)
<b>Reflections used for R-free</b>	1963 (194)
<b>R<sub>work</sub></b>	0.2784 (0.4586)
<b>R<sub>free</sub></b>	0.3120 (0.4967)
<b>Number of non-hydrogen atoms</b>	15852
<b>macromolecules</b>	15520
<b>ligands</b>	277
<b>solvent</b>	55
<b>Protein residues</b>	1888
<b>RMS(bonds) (Å)</b>	0.002
<b>RMS(angles) (°)</b>	0.6
<b>Ramachandran favored (%)</b>	94.72
<b>Ramachandran allowed (%)</b>	5.28
<b>Ramachandran outliers (%)</b>	0
<b>Rotamer outliers (%)</b>	3.76
<b>Clashscore</b>	13.37
<b>Average B-factors:</b>	74.21
<b>macromolecules</b>	74.11
<b>ligands</b>	84.98
<b>solvent</b>	48.56



**Table S2. Key contacts in IL-21 receptor complex**

Site IIa IL-21–IL-21R interface			
Hydrogen Bonds	$\gamma$ c	Dist. [Å]	IL-21
1	F:THR 105 [O $\gamma$ ]	2.75	D:ASP 37 [O $\delta$ ]
2	F:GLN 127 [N $\epsilon$ ]	3.12	D:SER 113 [O $\gamma$ ]
3	F:GLN 127 [O $\epsilon$ ]	3.52	D:GLN 116 [N $\epsilon$ ]

Site IIb IL-21R– $\gamma$ c interface			
Hydrogen Bonds	$\gamma$ c	Dist. [Å]	IL-21R
1	F:ARG 183 [N $\eta$ ]	3.17	E:GLU 136 [O $\epsilon$ ]
2	F:SER 146 [O $\gamma$ ]	2.81	E:GLU 170 [O $\epsilon$ ]
3	F:GLN 147 [N $\epsilon$ ]	2.77	E:LEU 156 [O]
4	F:SER 187 [O $\gamma$ ]	3.13	E:SER 158 [O $\gamma$ ]
5	F:SER 187 [O $\gamma$ ]	2.78	E:LEU 156 [O]
6	F:GLN 147 [O $\epsilon$ ]	3.12	E:LEU 156 [N]
7	F:SER 187 [O $\gamma$ ]	3.72	E:SER 158 [N]
8	F:SER 190 [O $\gamma$ ]	2.83	E:LEU 167 [N]
9	F:TYR 182 [O $\eta$ ]	2.70	E:LYS 134 [N $\zeta$ ]

Site III IL-21R–IL-21R interface			
Hydrogen Bonds	IL-21R	Dist. [Å]	IL-21R
1	H:HIS 24 [N $\delta$ ]	3.20	E:ASP 125 [O $\delta$ ]
2	H:HIS 53 [N $\epsilon$ ]	2.43	E:ASP 122 [O $\delta$ ]
3	H:TRP 148 [N]	3.17	E:ARG 144 [O]
4	H:TRP 148 [N]	2.91	E:ASP 146 [O]
5	H:TRP 148 [N $\epsilon$ ]	2.55	E:GLU 178 [O $\epsilon$ ]
6	H:ALA 149 [N]	2.90	E:ARG 144 [O]
7	H:THR 61 [O $\gamma$ ]	2.92	E:HIS 63 [N $\epsilon$ ]
8	H:ASP 122 [O $\delta$ ]	2.70	E:HIS 53 [N $\epsilon$ ]
9	H:ASP 125 [O $\delta$ ]	3.00	E:HIS 24 [N $\delta$ ]
10	H:ARG 144 [O]	3.10	E:TRP 148 [N]
11	H:ARG 144 [O]	2.67	E:ALA 149 [N]
12	H:ASP 146 [O]	2.73	E:TRP 148 [N]
13	H:GLU 178 [O $\epsilon$ ]	2.77	E:TRP 148 [N $\epsilon$ ]

Site III IL-21R–IL-21R interface			
Salt Bridges	IL-21R	Dist. [Å]	IL-21R
1	H:HIS 24 [N $\delta$ ]	3.20	E:ASP 125 [O $\delta$ ]
2	H:HIS 53 [N $\epsilon$ ]	2.43	E:ASP 122 [O $\delta$ ]
3	H:ASP 122 [O $\delta$ ]	2.70	E:HIS 53 [N $\epsilon$ ]
4	H:ASP 122 [O $\delta$ ]	2.95	E:HIS 53 [N $\epsilon$ ]
5	H:ASP 125 [O $\delta$ ]	3.00	E:HIS 24 [N $\delta$ ]

**Table S3. Cryo-EM data collection, refinement, and validation statistics**

<b>Protein</b>	<b>IL-21-IL-21R-<math>\gamma</math>c complex</b>
<b>EMD</b>	EMD-28278
<b><u>Data collection and processing</u></b>	
Magnification	45,000
Voltage (keV)	200
Electron exposure (e-/Å <sup>2</sup> )	50
Defocus range (μm)	-1.0 to -2.5
Pixel size (Å)	1.15
Symmetry imposed	C2
Initial particle images	1,444,277
Final particle images	57,295
Map resolution FSC threshold (Å)	0.143
Map resolution (Å)	3.7
<b><u>Model Fitting</u></b>	
Model used (PDB)	8ENT
Model resolution FSC threshold (Å)	0.5
Model resolution (Å)	4.2